119 related articles for article (PubMed ID: 28668900)
1. Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer.
Miyata K; Yotsumoto F; Fukagawa S; Kiyoshima C; Ouk NS; Urushiyama D; Ito T; Katsuda T; Kurakazu M; Araki R; Sanui A; Miyahara D; Murata M; Shirota K; Yagi H; Takono T; Kato K; Yaegashi N; Akazawa K; Kuroki M; Yasunaga S; Miyamoto S
Anticancer Res; 2017 Jul; 37(7):3955-3960. PubMed ID: 28668900
[TBL] [Abstract][Full Text] [Related]
2. Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer.
Izuchi D; Fukagawa S; Yotsumoto F; Shigekawa K; Yoshikawa K; Hirakawa T; Kiyoshima C; Ouk NS; Urushiyama D; Katsuda T; Miyata K; Ito T; Kurakazu M; Araki R; Sanui A; Miyahara D; Murata M; Ito H; Shirota K; Kuroki M; Yasunaga S; Miyamoto S
Anticancer Res; 2018 Jul; 38(7):4347-4351. PubMed ID: 29970572
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract][Full Text] [Related]
4. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
5. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
6. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
Yagi H; Yotsumoto F; Miyamoto S
Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
[TBL] [Abstract][Full Text] [Related]
7. Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.
Shetty P; Patil VS; Mohan R; D'souza LC; Bargale A; Patil BR; Dinesh US; Haridas V; Kulkarni SP
Ann Clin Biochem; 2017 Jul; 54(4):463-471. PubMed ID: 27496793
[TBL] [Abstract][Full Text] [Related]
8. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
10. M2 macrophages induce ovarian cancer cell proliferation via a heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop.
Carroll MJ; Kapur A; Felder M; Patankar MS; Kreeger PK
Oncotarget; 2016 Dec; 7(52):86608-86620. PubMed ID: 27888810
[TBL] [Abstract][Full Text] [Related]
11. Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA.
Hikita S; Yotsumoto F; Fukami T; Horiuchi S; Sanui A; Miyata K; Nam SO; Tsujioka H; Ueda T; Shirota K; Yoshizato T; Maeda K; Ishikawa T; Okuno Y; Kuroki M; Mekada E; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2553-9. PubMed ID: 21873174
[TBL] [Abstract][Full Text] [Related]
12. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
[TBL] [Abstract][Full Text] [Related]
13. High plasma levels of heparin-binding epidermal growth factor are associated with a more stable plaque phenotype and reduced incidence of coronary events.
Rattik S; Wigren M; Björkbacka H; Fredrikson GN; Hedblad B; Siegbahn A; Bengtsson E; Schiopu A; Edsfeldt A; Dunér P; Grufman H; Gonçalves I; Nilsson J
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):222-8. PubMed ID: 25359857
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells.
Koshikawa N; Mizushima H; Minegishi T; Eguchi F; Yotsumoto F; Nabeshima K; Miyamoto S; Mekada E; Seiki M
Cancer Sci; 2011 Jan; 102(1):111-6. PubMed ID: 20946474
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer.
Chung HW; Kong HY; Lim JB
World J Gastroenterol; 2015 Feb; 21(7):2080-8. PubMed ID: 25717241
[TBL] [Abstract][Full Text] [Related]
16. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
17. Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.
Miyata K; Yotsumoto F; Nam SO; Odawara T; Manabe S; Ishikawa T; Itamochi H; Kigawa J; Takada S; Asahara H; Kuroki M; Miyamoto S
Cancer Med; 2014 Oct; 3(5):1159-69. PubMed ID: 25060396
[TBL] [Abstract][Full Text] [Related]
18. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
19. Discovery of an Heparin-Binding Epidermal Growth Factor Domain Antibody from a Phage Library and Analysis of Its Inhibitory Effects in SKOV3 Cells.
Lü P; Qiu S; Pan Y; Shi S; Yu Q; Yu F; Miao L; Wang H; Chen K
Cancer Biother Radiopharm; 2023 Oct; 38(8):572-579. PubMed ID: 34529926
[No Abstract] [Full Text] [Related]
20. Possible pro-inflammatory role of heparin-binding epidermal growth factor-like growth factor in the active phase of systemic sclerosis.
Hirabayashi M; Asano Y; Yamashita T; Miura S; Nakamura K; Taniguchi T; Saigusa R; Takahashi T; Ichimura Y; Miyagawa T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
J Dermatol; 2018 Feb; 45(2):182-188. PubMed ID: 29044628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
